Titre : Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
link : Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?Annie Madden, Max Hopwood, Joanne Neale, Carla Treloar
Published: November 30, 2018 https://ift.tt/2So1xzn
Abstract
Recent advances in the efficacy and tolerability of hepatitis C treatments and the introduction of a universal access scheme for the new Direct Acting Antiviral (DAA) therapies in March 2016, has resulted in a rapid increase in the uptake of hepatitis C treatment in Australia. Despite these positive developments, recent data suggest a plateauing of treatment numbers, indicating that more work may need to be done to identify and address ongoing barriers to hepatitis C treatment access and uptake. This paper aims to contribute to our understanding of the ongoing barriers to DAA therapies, with a focus on people who inject drugs. The paper draws on participant interview data from a qualitative research study based on a participatory research design that included a peer researcher with direct experience of both hepatitis C DAA treatment and injecting drug use at all stages of the research process. The study’s findings show that residual barriers to DAA treatment exist at personal, provider and system levels and include poor venous access, DAA treatments not considered ‘core-business’ by opioid substitution treatment (OST) providers, and patients having to manage multiple health and social priorities that interfere with keeping medical appointments such as childcare and poor access to transport services. Further, efforts to increase access to and uptake of DAA hepatitis C treatment over time will require a focus on reducing stigma and discrimination towards people who inject drugs as this remains as a major barrier to care for many people.
Links:
View Full-Text Online
Download PDF
Thus articles Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
that is all articles Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? the link address https://newsaninpiration.blogspot.com/2018/12/beyond-interferon-side-effects-what.html
0 Response to "Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?"
Post a Comment